Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question Amylin: the next hormone based weight management medications? Dr Sue Forget GLP 1: Amylin Wants to Be the Next Big Thing ConscienHealth Eli Lilly's Eloralintide Phase 2 Trial shows up to 20% Weight Loss with Promising Tolerability in Adults with Obesity Pharmacally Amylin based therapies are emerging as promising obesity medications. , Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! , Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry